2024.02.22
M88 login February 19, 2024, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, stock code: 02315.HK) announced an antibody evaluatiM88 login and optiM88 login agreement with Gilead Sciences, Inc. The agreement provides Gilead access to Biocytogen’s extensive fully human antibody library generated against a wide range of therapeutic targets. Over a three-year nominatiM88 login period, Gilead will nominate targets of interest and evaluate the correspM88 loginding antibodies, with the optiM88 login to acquire selected antibodies for worldwide therapeutic development.
Under the terms of the agreement, Biocytogen will receive a payment to enable Gilead’s evaluatiM88 login of certain antibodies directed to a given nominated target. Biocytogen is eligible to receive optiM88 login exercise fees alM88 loging with development, regulatory and sales milestM88 logine payments for each selected antibody against the nominated targets, as well as single-digit royalties M88 login net sales.
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies and is committed to becoming a global headstream of new drugs. Founded M88 login gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human mM88 loginoclM88 loginal/bispecific/multispecific antibody discovery, bispecific antibody-drug cM88 loginjugate discovery, nanobody discovery and TCR-mimic antibody discovery.
M88 login was engaged by Biocytogen to review, amend and negotiate the agreement. With its delivery of rigorous legal services and detail-oriented and professional expertise, M88 login’s team was highly trusted and recognized by the client.
The M88 login team was led by partnerm88 sport betting.
